US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Gamida Cell Ltd.

< Previous 1 2 Next >
News headline image
Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell Issues Update on Israel Operations
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell to Present Corporate Highlights at 2023 Cell & Gene Meeting on the Mesa
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
First Patient Receives Gamida Cell's Omisirge™ (omidubicel-onlv)
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell to Present Corporate Highlights at the H.C. Wainwright 25th Annual Global Investment Conference
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell to Report Second Quarter 2023 Financial Results
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell’s Omisirge® (omidubicel-onlv)
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell Appoints Terry Coelho as CFO
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell Announces Pricing of $23 Million Public Offering of Securities
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell Announces Launch of Public Offering of Securities
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell Announces Changes to Board of Directors
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell Announces Closing of $25 Million Financing With Highbridge
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell Provides Regulatory Update on Omidubicel
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
News headline image
Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting
From Gamida Cell Ltd.
Via Business Wire
Tickers GMDA
< Previous 1 2 Next >